Clinical Trial Update: A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 1b/2 dose-escalation study of elotuzumab in relapsed multiple myeloma has completed phase 2 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elotuzumab (elotuzumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Hematologic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-01-10